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Abstract: Loss of p53 function compromises genetic homeostasis, which induces deregulated 
DNA replication, damages DNA, and subsequently results in increased resistance to anticancer 
agents. Pharmacological approaches using recombinant adenoviruses (Ad) have been developed 
to restore the p53 functions. Another approach for gene medicine is to modify Ad replication 
in a tumor-speciﬁ  c manner, which induces tumor cell death without damaging normal tissues 
in the vicinity. The Ad-derived gene medicines, Ad expressing the wild-type p53 gene and 
replication-competent Ad defective of the E1B-55kDa gene, have been tested for their clinical 
feasibility and became commercially available in China. These agents demonstrated their 
antitumor activities as a monotherapy and in combination with conventional chemotherapeutic 
agents. In this article, we summarize the outcomes of clinical trials in China, most of which 
have been published in domestic Chinese journals, and discuss potential directions of cancer 
gene therapy with these agents.
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Introduction
Cancer is currently one of the main causes of death in Western and Asian societies. 
Treatments for advanced-stage cancer are often difﬁ  cult with a limited efﬁ  cacy despite 
multimodal therapeutic strategies. Novel approaches are required to improve the 
prognosis. A molecular targeting with small-sized synthetic chemicals in a certain 
type of cancer is currently available and furthermore many candidate molecules are 
under investigation. Gene therapy is also a possible treatment modality and over the 
past decades has been investigated preclinically and clinically for their feasibility. 
According to data published in the Journal of Gene Medicine, there have been 1309 
approved clinical trials in the world until July 2007 and 66.5% of the trials targeted 
cancer. Historically, a number of clinical trials have been conducted in the Western 
world but none of the gene medicines have yet been approved by governmental 
authorities for commercialization. In contrast, adenoviruses (Ad) expressing the human 
wild-type p53 gene and Ad defective of the E1B-55 kDa molecule, both of which 
were originally developed and clinically examined for the efﬁ  cacy in USA, have been 
admitted in China. The Ad agents have become the ﬁ  rst commercially available gene 
medicine in the world.
In October 2003, the State Food and Drug Administration (SFDA) of China 
approved type 5 Ad bearing the human wild-type p53 gene (Ad-p53) for the treat-
ment of head and neck cancer. Ad-p53 (Gendicine®, Shenzhen SiBiono GeneTech, 
Shenzhen, China [now incorporated into Benda Pharmaceutical, Wuhan, China]) 
have been initially developed by Introgen Therapeutics (Advexin®, Austin, TX, USA) 
for head, neck, and lung cancer treatment. While Introgen was working to obtain US Drug Design, Development and Therapy 2008:2 116
Ma et al
FDA approval, SiBiono successfully completed clinical 
studies and launched the product. In November 2005, SFDA 
also approved type 5 Ad defective of the E1B-55 kDa mol-
ecule for head and neck cancer treatment. The E1B-defective 
Ad were originally developed in USA and were representa-
tively called ONYX-015 (Onyx Pharmaceuticals, Emeryville, 
CA, USA). While ONYX-015 had been investigated for the 
clinical efﬁ  cacy, a Chinese bioventure company, Shanghai 
Sunway Biotech (Shanghai, China), independently developed 
E1B-55 kDa-deleted Ad, completed their clinical studies, and 
commercialized the medicine (Oncorine®) in 2006. Sunway 
Biotech has also acquired the exclusive license of ONYX-
015 in the world.
Since the majority of these clinical results conducted in 
China has not been well reported in an international confer-
ence, many researchers in the Western medical societies have 
been unaware of the recent progress of cancer gene therapy 
in China until recently. A large number of cancer patients 
including Caucasians have received the gene medicine in 
China and the clinical outcomes were published in major 
Chinese domestic journals. Many non-Chinese medical sci-
entists were unfortunately unable to access the information. 
Scientists in the Western countries have recently noticed a 
successful launching of Gendicine and Oncorine in a Chinese 
market and come to pay close attention to Chinese clinical 
data. It is obvious that such commercialization is a remark-
able progress for the development of cancer gene therapy 
but difﬁ  culties in accessing such Chinese information were 
not beneﬁ  cial for non-Chinese communities as well as the 
Chinese society. In this review article, we summarize the cur-
rent status of Ad-p53 and E1B-defective Ad (represented by 
ONYX-015) and show the clinical data obtained in Chinese 
medical institutions.
Clinical trials with Ad-p53
Mechanism of the antitumor effects
Gendicine and Advexin are essentially the same in viral struc-
ture. They are recombinant type 5 Ad in which the E1 region is 
replaced by either a Rous sarcoma virus (Gendicine) or a cyto-
megalovirus (Advexin) promoter linked with the human wild-
type p53 gene and a poly (A) tail. The Ad-p53 can produce a 
good amount of p53 protein in target cells and achieve a variety 
of cellular responses. The wild-type p53 plays a central role in 
maintaining genetic stability in human cells. About a half of 
human malignancies show loss of p53 functions, resulting in 
increased resistance to DNA-damaging agents (Shiraishi et al 
2004). Transduction of tumors with Ad-p53 has demonstrated 
inhibition of the tumor growth and enhanced the susceptibility 
to anticancer agents (Blagosklonny et al 1998; Inoue et al 
2000; Schuler et al 2001; Sah et al 2003; Schwartzenberg et al 
2004; Wang et al 2006). Animal experiments also showed 
the therapeutic effects to various cancers by way of intratu-
moral injection and in combination with an anticancer agent 
or agents. Several lines of the experiments suggested that 
Ad-p53 produced better antitumor effects to tumors bearing 
mutated p53 genes than in those with the wild-type p53 gene 
(Cerrato et al 2001; Eisold et al 2004). Ad are not integrated 
into host genomes; subsequently a possible risk of secondary 
Ad-mediated tumorigenesis by activating an oncogene and 
inactivating a tumor suppressor gene is extremely low and in 
fact type 5 Ad have not induced tumors in human.
A number of clinical studies demonstrated that intratu-
moral injection of Ad-p53 resulted in vector-mediated p53 
gene expression in various types of tumors and thus produced 
antitumor activities (Clayman et al 1998; Habib et al 1999; 
Swisher et al 1999; Singh et al 2002). The clinical trials 
showed that Ad-p53 administration was safe and well toler-
ated with minimal adverse reactions to most of the patients. 
The minimal unfavorable effects exhibited that Ad-p53 
had a high therapeutic window and consequently implied 
that Ad-p53 could be used in combination with other conven-
tional treatments, chemotherapy, and/or radiation therapy. The 
expressed p53 protein achieved antitumor activities through 
a number of mechanisms (Muller et al 1998; Nemunaitis et al 
2000; Pal et al 2001; Pagliaro et al 2003; Quist et al 2004; 
Rosenblum et al 2004; Rother et al 2004; Sabine 2004). 
(a) Induction of apoptotic pathways in tumor cells, which 
is mediated by a variety of machinery (Muller et al 1998; 
Bouvard et al 2000; Matsuda et al 2002; Chipuk et al 2004; 
Leu et al 2004; Taha et al 2004). (b) Blockage of survival 
signal pathways in tumor cells (Singh et al 2002; Yin et al 
2003; Rother et al 2004). (c) Activation of host immune sur-
veillance systems (Yen et al 2000; Cerwenka and Lanier 2003; 
Rosenblum et al 2004). (d) Down-regulation of the multi-drug 
resistance genes (Krishna and Mayer 2000), which improves 
susceptibility of tumor cells to chemotherapy (e) Inhibition 
of angiogenesis (Dameron et al 1994; Pal et al 2001) and 
metastasis by suppressing matrix metalloproteinase (Toschi 
et al 2000; Ala-aho et al 2002; Sun et al 2004).
Clinical results obtained with Gendicine 
in China
Several phase II and III clinical trials have been conducted 
in conjunction with Gendicine and conventional therapies 
and the combinatorial modality produced better therapeutic 
benefits than Gendicine alone in most of the studies. Drug Design, Development and Therapy 2008:2 117
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Gendicine has been currently approved only for head and 
neck cancer with intratumoral injection and in combination 
with chemotherapy. A number of clinical studies in fact have 
been performed with an off-labeled use of Gendicine, which 
is allowed with permission of individual institutional ethical 
committees. The agent has been tested as an off-labeled use 
for lung cancer, breast cancer, mesothelioma, and esophageal, 
hepatocellular, gastric, colorectal, and pancreatic carcinomas. 
These studies examined possible additional effects of Gen-
dicine to conventional therapies including hyperthermia. 
Gendicine has been usually administered intratumorally 
with 1 × 1012 viral particles (vp) irrespective of tumor 
types. Various administration routes have been investigated 
including pleural and peritoneal cavity perfusion and even 
intra-arterial as well as intravenous administration. All the 
publications mentioned that the most common adverse effect 
of Gendicine was low-grade fever which was self-cured and 
suggested that Gendicine was safe and effective. The major 
concern of the clinical reports is however that the studies 
did not follow a strict treatment schedule and the selection 
criteria of patients were ambiguous. Most of the studies 
involved a relatively small number of the patients and it 
seems that they were accumulated respective case reports. 
Nonetheless according to Dr. Peng’s presentation at the 
European Society of Gene and Cell Therapy conference in 
2007, more than 7,000 cancer patients including 500 non-
residents in total have received Gendicine and he expected 
more than 10,000 patients at the end of 2007. A phase IV 
study seems to be initiated in China although such informa-
tion is not well documented.
Head and neck squamous cell carcinoma
The majority of head and neck squamous cell carcinoma 
treated with Gendicine (85%) is nasopharygeal carcinoma 
(Chen et al 2003; Zhang et al 2003) because of the high 
incidence in China. The multicentered trial was conducted 
with 135 patients, and 77% were not eligible for surgical 
resection with stage III or IV and were chemotherapy-
resistant. The study thereby did not exclude early-staged 
patients. The protocol was consisted with two therapeutic 
arms: a combination of Ad-p53 and radiotherapy or 
radiotherapy alone with the same irradiation doses. In 
the combination therapy, 1 × 1012 vp Gendicine was 
administered before the radiotherapy and the tumor 
responses were evaluated with a computed tomography 
(CT) or magnetic resonance imaging. The combination 
therapy demonstrated that the complete remission (CR) and 
partial response (PR) rate were 64% and 29%, respectively, 
whereas the radiation alone group showed that CR and 
PR were 19% and 60%, respectively. The report thereby 
concluded that Gendicine in combination with radiotherapy 
produced synergistic effects.
Hepatocellular carcinoma
Gendicine was tested for 68 and 82 advanced hepa-
tocellular carcinoma patients in combination with 
chemotherapy and the chemotherapy alone, respectively 
(Guan et al 2005) (Table 1). Camptothecin, doxorubicin, 
and 5-fluorouracil were used together with embolization. 
Gendicine (1–4 × 1012 vp) was administered at multiple 
points into tumor masses under CT guidance every week 
48–72 hours after the embolization. Although the precise 
treatment schedule and clinical features of the patients 
were not well described, the report mentioned that the 
response rates of the combination and the control group 
were 67.6% and 51.2%, respectively (p  0.05) and the 
6-month survival rate was 76.5% in the combination and 
23.2% in the control (p  0.01). The study also reported 
Table 1 Off-label usage with Gendicine in China
Type of tumor Number 
of patients
Administration routes Combination with 
other therapies
Reference
Hepatocellular carcinoma 68 CT-guided intratumor 
injection
Chemotherapy Guan et al 2005
Lung cancer 15 CT-guided pneumocentesis None Weng et al 2004
15 CT-guided pneumocentesis 
or via bronchial artery
Chemotherapy Guan et al 2005
Soft tissue sarcoma 12 Intratumor injection Hyperthermia Xiao et al 2007
Malignant effusions by 
malignant mesothelioma 
and alimentary tract 
carcinoma
32 Peritoneal injection Hyperthermia Liu et al 2006
Abbreviation: CT, computed tomography.Drug Design, Development and Therapy 2008:2 118
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improvement of quality of patients’ life with Gendicine 
(Guan et al 2005).
Other types of cancer
Gendicine has been investigated for the efﬁ  cacy to advanced 
lung cancer together with and without chemotherapeutic 
agents (Weng et al 2004) and for soft tissue sarcoma with 
and without radiotherapy and hyperthermia (Xiao et al 2007). 
Due to the limited patient numbers, it is difﬁ  cult to draw any 
conclusions (Table 1).
Factors involved in Ad-p53-mediated 
effects
There are several factors that influence the efficacy of 
Ad-p53-mediated antitumor effects. One of the major factors 
is the expression level of type 5 Ad receptors. The receptors 
of type 5 Ad are consisted of coxsackie adenovirus recep-
tor (CAR) and integrin αvβ3 and αvβ5. The expression of 
CAR, a primary receptor for Ad, is often down-regulated in 
human tumors, which decreases the transduction efﬁ  cacy 
with Ad vectors. Consequently, human tumors with a low 
CAR expression level showed decreased therapeutic efﬁ  -
ciency (Zeimet and Marth 2003). The infection efﬁ  ciency is 
also impeded by the presence of Ad-neutralizing antibodies, 
which are produced by Ad administration irrespective of the 
injection sites. It is estimated that 60% or more of the world 
population, although it depends on area, are positive for anti-
Ad5 antibody prior to the treatment and subsequently even 
single Ad administration induced high titered neutralizing 
antibody with ease.
The integrity of signal transduction downstream of the 
p53 pathways also determines the efﬁ  cacy. The major-
ity of preclinical studies showed that Ad-p53 produced 
better therapeutic effects to tumors with mutated p53 genes 
than those with wild-type p53 gene (Katayose et al 1995; 
Blagosklonny and el-Deiry 1996; St John et al 2000). 
Recent clinical studies by Introgen also demonstrated the 
correlation between the efﬁ  cacy of Ad-p53 and endogenous 
p53 gene status and suggest that the status is a biomarker 
to predict the effectiveness. Expression of p53 restores an 
appropriate activation of the p53 downstream signaling in 
p53-mutated tumor cells probably because p53-mutated 
cells often have intact p53-downstream pathways. Instead, 
wild-type p53-bearing tumors cells could have mutated p53-
downstream cascades, which consequently give resistance to 
p53-mediated cellular responses despite super-induction of 
p53. Zeimet and Marth (2003) suggested that tumors with 
epigenetically deregulated the p53 gene also showed the 
similar responses to Ad-p53 as found in the tumors with a 
dominant-negative p53 mutation.
Clinical studies with Ad defective 
of E1B-55 kDa
Development of oncolytic Ad
Ad-p53 lack the E1 region and are replication-incompetent. 
The antitumor effects thereby depend on the expression 
level of transduced p53 and on the integrity in p53-mediated 
cascades in the target tumors. The other approach to produce 
Ad-mediated antitumor effects is to use the cytotoxicity 
that is associated with the viral propagation within cells. 
Recombinant Ad which can replicate within tumors is a 
therapeutic strategy because such Ad replication triggers 
a cytotoxic mechanism different from that by conventional 
anticancer agents.
Wild-type Ad can replicate efﬁ  ciently in epithelial cells 
and are potential cytolytic to tumors. An early clinical trial 
in the 1950’s showed that intratumoral administration of 
the wild-type Ad of different types induced regression of 
cervical carcinomas; however, the therapeutic effects were 
transient. The clinical application of such viruses-medi-
ated cytotoxicity was thereby abandoned due to the lack of 
sustained clinical efﬁ  cacy (Smith et al 1956). More recently, 
recombinant virus technology has led to the development 
of conditionally replicating Ad that are designed to selec-
tively replicate in tumor cells while leaving normal cells 
undamaged. An advantage of such replication-competent 
Ad with an oncolytic property is a continuous spread of 
the virus progenies released from damaged tumors into 
neighboring tumor cells even if the initial efﬁ  ciency of 
transduction is relatively low. The ﬁ  rst generation of such 
conditionally replicative Ad (also termed as CRAd) was 
ONYX-015 (dl1520 or CI-1042) (Bischoff et al 1996). 
ONYX-015 is a chimeric Ad consisting of type 2 and 
type 5 structures with a partial abrogation of the E1B-55 
kDa-encoding region, which results in deletion of the protein 
synthesis. Initially ONYX-015 was considered to efﬁ  ciently 
replicate only in cells lacking functional p53 and to induce 
signiﬁ  cant regression of human tumors developed in mice 
due to the tumor-speciﬁ  c viral replication (Bischoff et al 
1996; Rogulski et al 2000). The E1B-55 kDa protein and 
E4 orf  3 and E4 orf6 proteins binds to p53 and inhibits the 
p53-mediated apoptosis; subsequently the viral production 
was enhanced (Yew and Berk 1992). Hypothetically ONYX-
015 would not be able to prevent p53-induced apoptosis 
in normal cells and replicate in cells lacking functional Drug Design, Development and Therapy 2008:2 119
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p53, as found in the majority of human tumors (White 1994; 
Fulci and Van Meir 1997). Several studies with a limited 
number of cell lines demonstrated greater cytotoxicity of 
ONYX-015 to p53-mutated tumors compared to those with 
the wild-type p53 gene (Bischoff et al 1996). Subsequent 
studies however denied the correlation between the p53 
status and replicative capacity of ONYX-015 (Rothmann 
et al 1998). Although the precise mechanism of viral replica-
tion with respect to the p53 status remains unclear, empirical 
evidences supported the preferential lysis of tumor cells in 
comparison with normal cells (Reid et al 2002; Nemunaitis 
et al 2003).
ONYX-015 has been clinically examined for head and 
neck cancer and liver metastases of colon cancer with various 
delivery routes (Reid et al 2002; Nemunaitis et al 2003; Chu 
et al 2004). Overall, the trials have shown an acceptable 
safety proﬁ  le even when the Ad were systemically delivered. 
The therapeutic efﬁ  cacy was not however satisfactory when 
it was used as a single agent but the combinatory use with 
anticancer agents enhanced the activities. For example, a 
response rate of ONYX-015 together with cisplatin and 
5-ﬂ  uorouracil, more than 50% tumor reduction 1 month after 
the treatment, was 63% for head and neck cancer whereas 
that of ONYX-015 and the chemotherapy alone were 14% 
and 30%–40%, respectively. Despite the promising out-
comes, clinical development of ONYX-015 in USA has been 
discontinued, but not because of medical or scientiﬁ  c issues. 
Currently the next generations of oncolytic Ad in which 
the E1 region is activated by an exogenous transcriptional 
region and/or E3 region is replaced with a therapeutic trans-
gene such as Escherichia coli cytosine deaminase, an enzyme 
that can convert 5-ﬂ  uorocytosine into its toxic metabolite, 
have been examined for its efﬁ  cacy and clinical feasibility 
(Zhan et al 2005). The expression of a transgene in the E3 
region is regulated under the control of endogenous viral late 
gene regulatory elements and linked with the replication of 
oncolytic Ad (Royds et al 2006).
Clinical application of oncorine in China
A phase III study of ONYX-015 for head and neck cancer 
has been suspended in USA but Oncorine (the developmental 
code name was H101), which is type 5 Ad and essentially 
the same structure as ONYX-015, had been clinically tested 
for its efﬁ  cacy in China. Following phase I and phase II 
clinical trails which included 191 patients with 13 kinds 
of carcinoma such as head and neck cancer, breast cancer, 
and colon cancer, a phase III clinical trail with Oncorine 
on head and neck cancer was performed with intratumoral 
injections. It seems that the clinical studies of Oncorine were 
more convincing than those of Gendicine and the clinical 
results were comparable to that of ONYX-015 in USA. The 
maximal tolerance dose was 2 × 1012 vp but lower dose were 
also effective.
Head and neck squamous cell carcinoma
Hu and colleagues (2006) reported that 123 patients were 
evaluable in a phase III study (Xia et al 2004), which did not 
report the p53 status of each tumor. The patients received both 
Oncorine and chemotherapeutic agents; the combination of 
either cisplatin +5-ﬂ  uorouracil or adriamycin +5-ﬂ  uorouracil. 
The study included patients who had not received any che-
motherapy before as well as those who were resistant to the 
chemotherapy. Oncorine was injected intratumorally at the 
dose of 5 × 1011 vp for 5 consecutive days for a treatment 
course. The adverse effects were not serious and well-tol-
erated; fever, local pain at the injection site, and ﬂ  u-like 
symptoms were frequently reported. An objective response 
rate of the group that received both Oncorine and anticancer 
agents and that of the chemotherapy group as a control were 
72.7% and 40.4%, respectively. The combination therapy was 
more effective to those who were naïve to the chemotherapy 
(79.0% response rate). Oncorine had also been examined for 
the efﬁ  cacy with 56 nasopharyngeal carcinoma patients in 
the combination of chemotherapy (cisplatin  +5-ﬂ  uoroura-
cil). Oncorine showed better objective response rates in the 
combination with chemotherapy (75.6%) than chemotherapy 
alone (57.1%) but the results were statistically insigniﬁ  cant 
(p = 0.081). Among the patients who did not have prior 
chemotherapy, the group of Oncorine with chemotherapy 
achieved better response rates than that of chemotherapy 
alone (86.5% to 59.4%, p  0.05).
Interestingly, the patients who had fever at the time of 
Oncorine administration had better objective responses than 
those without fever although statistically not signiﬁ  cant. The 
precise mechanism remains uncharacterized but preclinical 
data suggest that it was attributable to elevated expression 
of the heat shock protein, which facilitated late viral RNA 
export to cytoplasm and subsequently enhanced viral replica-
tions (O’Shea et al 2005). The preclinical study also showed 
that ONYX-015 RNA was poorly transported to cytoplasm 
in normal cells whereas the transportation was up-regulated 
in tumors with unknown mechanisms. They suggested that 
the differential transfer of viral RNA could contribute to 
the tumor-specific cell lysis with ONYX-015. Another 
study of trimodal combination of Oncorine, chemotherapy, 
and radiotherapy was conducted for 56 patients with Drug Design, Development and Therapy 2008:2 120
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nasopharyngeal carcinoma (Lu et al 2006). Although clinical 
results of the control group without Oncorine administra-
tion were not shown, the trimodal therapy showed 71.4% 
of complete responses and 28.6% of partial responses with 
minimal adverse effects such as a transient fever and mucosal 
ulcer in the oral cavity.
Nonsmall cell lung cancer
A small number of nonsmall cell lung cancer patients have 
received intratumoral injection of Oncorine (1.5 × 1012 vp) 
together with vinorelbine and cisplatin. In evaluable 19 patients 
who received Oncorine and the chemotherapy, 5 and 10 
patients showed partial response and stable diseases, respec-
tively, while 3 and 9 cases for partial response and stable 
diseases in 17 patients with the chemotherapy alone. Like-
wise, one year survival rate and median time to progression 
were not signiﬁ  cantly different between the two groups. 
Intratumoral injection of Oncrine was safe but the efﬁ  cacy 
was not as great as in the case of head and neck cancer 
(Zhou et al 2006).
Clinical feasibility of ONYX-015 in combination 
treatment
Heterogenous or decreased CAR expression in tumors 
also hampered ONYX-015-mediated antitumor effects as 
observed in the case of Ad-p53 (Zeimet and Marth 2003). 
In addition, many kinds of tumor cells did not support viral 
replication of ONYX-015 irrespective of the p53 status. 
Recent studies however shed light on a heat shock protein 
which seems to differentially regulate the viral replication 
between tumors and normal cells (Huang et al 2003; Wang 
et al 2005). Although the role of thermal effects in the pref-
erential viral replication in tumors is not well characterized, 
ONYX-015-resistant cells are sensitized by the induction of 
the heat shock protein (Hu et al 2006) and interestingly, the 
clinical data implied better clinical outcomes in the patients 
with a mild fever after ONYX-015 administration. Heat 
shock proteins are commonly up-regulated in tumor cells 
and could explain the preferential cytotoxicity of ONYX-015 
to tumors. Induction of heat shock responses by pharmaco-
logical agents such as benzoquinoid ansamycins or by local 
hyperthermia can improve the efﬁ  ciency and is a possible 
combinatory strategy with ONYX-015.
The trial with hyperthermia was started 1 day after the 
ﬁ  rst viral injection. The injected tumor sites were warmed 
with a radio-frequency heating instrument for 5 days. The 
outcomes are not reported due to a limited patient number 
but the research group raised a possibility of enhanced 
clinical beneﬁ  ts. Heat shock proteins have inﬂ  uence on 
antigen presentation in which the proteins bind putative 
tumor antigens. Increased antigenicity through class I and 
II of major histocompatibility complexes favors activation 
of CD8+ and CD4+ T cells and subsequently up-regulates 
cell-mediated immunity.
Combination with chemotherapy showed better thera-
peutic effects but anticancer agents themselves can inhibit 
the viral proliferation. Several agents are now clinically in 
use with Oncorine but careful evaluation will be required 
for clinical outcomes and the viral replications. Multiple 
injection of Ad generates anti-Ad responses which could be 
beneﬁ  cial to prevent systemic viral spread but inhibitory to 
viral spread into tumors in the vicinity.
Conclusions
A number of clinical trials have been conducted mainly in 
USA; however, none of the agents are commercially avail-
able in the Western markets. There are several reasons for 
the delayed governmental approval. During the approval 
processing, two kinds of medicine, which are originally devel-
oped in bioventure companies in USA, have been approved in 
China; however, the clinical studies from China in general were 
not adequately organized judged by the standards of Western 
medical societies. These reports are sometimes fragmentary 
and merely summarize respective case reports. In particular 
the studies often did not include a well-controlled group and 
long-term survival data. There is also a major difference in the 
clinical outcomes between the Chinese and Western studies, 
in which the Chinese studies showed better therapeutic effects 
with the same Ad vectors. One of the reasons is the differen-
tial eligibility criteria; Chinese studies sometimes included 
early staged patients who should be treated with a standard 
conventional therapy. Secondly, Chinese studies often use the 
gene medicine in particular in Ad-p53 cases as an adjuvant to 
the standard therapy. It is not wise at this moment to directly 
compare the clinical outcomes since several factors are not 
the same among the studies.
The commercialization nevertheless has given an 
opportunity for medical scientists to assess the potential 
clinical beneﬁ  ts of the gene medicine. In addition, it has also 
enabled an off-labeled use of the gene medicine in China 
with permission from an individual institutional ethical 
committee. These current situations lead us to re-evaluate 
the clinical data obtained in China. All the data indicated 
that the gene medicine were safe with minimal adverse 
reactions and seems to be effective in combination with 
other therapies.Drug Design, Development and Therapy 2008:2 121
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Ad-p53 can be used in combination with current standard 
protocols. More than 7,000 cancer patients have received 
Ad-p53 and many of them were inoffensively treated with a 
combinatory use of radiotherapy and/or chemotherapy. The 
treatments with Oncorine in China have been also conducted 
with the combination and the clinical outcomes are similar as 
those performed with ONYX-015 in USA. Clinical trials con-
ducted in both countries with Ad-p53 or Ad defective of E1B-
55 kDa gene showed that the gene therapy were safe and could 
be beneﬁ  cial for the cases in which conventional anticancer 
treatments have failed; however, many kinds of concerns and 
medical questions regarding Ad-p53 and Oncorine administra-
tion in the clinical settings remain unanswered. Several issues 
such as limited applicability of the administration due to the 
topological localization are also clinically important. Currently 
the Ad are injected intratumorally with good tolerability and 
moderate clinical activity, while it would be better to deliver 
intravenously for various types of advanced cancers. Targeting 
to cancer with speciﬁ  city is also one of the directions to be 
investigated. Cancer- and/or tissue-speciﬁ  c modiﬁ  cations of 
viral coat proteins which can change the vector tropism will 
increase the selectivity to cancer and consequently reduce the 
toxicity. Similarly, a new generation of replicative Ad vectors, 
placing the expression of therapeutic genes under the control 
of tumor-speciﬁ  c promoters or transcriptional control regions 
could be a strategy and in fact several trials are also conducted 
(Deweese et al 2001).
A number of clinical trials for cancer have been planned 
with replication-incompetent and -competent Ad. Clinical data 
from Chinese studies provides us a number of suggestions and 
implications, which would be useful for future clinical studies. 
In particular, growing numbers of the patients who received 
the gene medicine in various hospitals in China increase the 
necessity for phase IV studies. The Chinese clinical studies, 
when completed at an international standard level, must be 
enormously valuable in orienting a future direction of gene 
medicine. On the other hand, the director of SFDA was sen-
tenced for bribery to exercise his power over approval of new 
medicines in China in 2007. It raised a serious concern in the 
domestic and the international medical and pharmacological 
societies. Although the Chinese gene medicine companies 
declared that they were not involved in the corruption, the 
approval process of gene medicines in China will be more 
strictly controlled and monitored in future.
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